Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI

JACC: Cardiovascular Interventions(2021)10.1016/j.jcin.2020.11.046Source: DataRank Database

Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI is a research paper published in JACC: Cardiovascular Interventions (2021). On theSindex it has a DataRank of 0. It has been cited 38 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access38 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (35 grants)Impact (FWCI 4.53)OA: greenTopics (29)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (63)

Roxana Mehran ORCID,Anna Franzone ORCID,Bruno R. da Costa ORCID,Usman Baber ORCID,Raffaele Piccolo ORCID

Live enrichment

PubMed:33602441 OpenAlex:https://openalex.org/W3130386910

University of Florida

Grant: UL1 TR000064

National Human Genome Research Institute

Grant: U01 HG007269

British Heart Foundation

Grant: CS/15/7/31679

GE Healthcare

Gilead Sciences

Medicines Company

Medtronic

St. Jude Medical

Duke Clinical Research Institute

Eisai

Boston Scientific Corporation

Defence Science Institute

Merck

Siemens Medical Solutions USA

Abbott Vascular

Boehringer Ingelheim

Chiesi Farmaceutici

Novartis Pharmaceuticals Corporation

Scott R. MacKenzie Foundation

National Center for Advancing Translational Sciences

Abbott Laboratories

Amarin Pharma

Janssen Pharmaceuticals

National Institutes of Health

Amgen

AstraZeneca

Foundation for Cardiovascular Research

Janssen Scientific Affairs

Johnson and Johnson

Bayer

Bristol-Myers Squibb

CSL Behring

Eli Lilly and Company

OrbusNeich

Portola Pharmaceuticals

FWCI

4.53

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: cc-by-nc-nd

repositoryhttps://ruj.uj.edu.pl/xmlui/handle/item/270435

publisherhttps://api.elsevier.com/content/article/PII:S1936879820324584?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1936879820324584?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jcin.2020.11.046

Fields of Study

Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction ResearchCoronary Interventions and DiagnosticsDrug Therapy, CombinationDual Anti-Platelet TherapyHumansPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsTicagrelorTreatment Outcome

MeSH Terms

TicagrelorDual Anti-Platelet TherapyDrug Therapy, CombinationHumansPlatelet Aggregation InhibitorsTreatment OutcomePercutaneous Coronary Intervention

Keywords

TicagrelorConventional PCIMedicineDual (grammatical number)CardiologyInternal medicinePercutaneous coronary interventionMyocardial infarctionMeta-analysisaspirinDaptP2y(12) Inhibitors

Sustainable Development Goals

SDG 0: Good health and well-being